Streamex（STEX）株式概要
医療機器テクノロジー企業であるStreamex Corp.は、米国で電気生理学用の高度なデジタル信号処理ソリューションを提供している。 詳細
STEX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Streamex Corp. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.83 |
| 52週高値 | US$7.44 |
| 52週安値 | US$0.66 |
| ベータ | 2.02 |
| 1ヶ月の変化 | 9.42% |
| 3ヶ月変化 | -34.91% |
| 1年変化 | -83.92% |
| 3年間の変化 | -84.82% |
| 5年間の変化 | -97.28% |
| IPOからの変化 | -98.96% |
最新ニュース
ナラティブ更新 • Aug 19
STEX: New Partnerships And Gold Focus Will Support Future Liquidity Expansion
Analysts cut their Streamex price target to $4 from $8, as slower than hoped adoption of the GLDY product, softer Q2 EPS and adjusted EBITDA, and a tighter focus on gold launches with moderated marketing spend reshape expectations. Analyst Commentary Recent analyst commentary on Streamex focuses on how slower GLDY uptake and softer Q2 profitability metrics affect the risk and reward trade off at the new US$4 price target.ナラティブ更新 • Jun 26
STEX: New Partnerships Will Support Future On Chain Liquidity Expansion
Analysts have revised Streamex's fair value estimate from $12 to $8 after recent research updates, reflecting a more cautious view on the pace of GLDY growth while still noting support from the company's new partnerships. Analyst Commentary Recent research on Streamex focuses on how the slower than hoped GLDY rollout and new partnership announcements affect the stock's valuation and growth profile.Recent updates
ナラティブ更新 • Aug 19
STEX: New Partnerships And Gold Focus Will Support Future Liquidity Expansion
Analysts cut their Streamex price target to $4 from $8, as slower than hoped adoption of the GLDY product, softer Q2 EPS and adjusted EBITDA, and a tighter focus on gold launches with moderated marketing spend reshape expectations. Analyst Commentary Recent analyst commentary on Streamex focuses on how slower GLDY uptake and softer Q2 profitability metrics affect the risk and reward trade off at the new US$4 price target.ナラティブ更新 • Jun 26
STEX: New Partnerships Will Support Future On Chain Liquidity Expansion
Analysts have revised Streamex's fair value estimate from $12 to $8 after recent research updates, reflecting a more cautious view on the pace of GLDY growth while still noting support from the company's new partnerships. Analyst Commentary Recent research on Streamex focuses on how the slower than hoped GLDY rollout and new partnership announcements affect the stock's valuation and growth profile.新しいナラティブ • Apr 09
Tokenized Commodity Yield Platform Will Benefit From Growing Real World Asset Adoption
Catalysts About Streamex Streamex operates a capital light platform focused on tokenized commodity assets such as yield bearing gold and planned silver, copper and energy linked products. What are the underlying business or industry changes driving this perspective?分析記事 • Dec 12
Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now
Key Insights BioSig Technologies will host its Annual General Meeting on 18th of December Salary of US$865.7k is part...分析記事 • Dec 14
Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why
Shareholders of BioSig Technologies, Inc. ( NASDAQ:BSGM ) will have been dismayed by the negative share price return...Seeking Alpha • Oct 07
BioSig in acquisition pact with San Antonio Hospital for cardiac signal system
Medical device maker BioSig Technologies, Inc. (NASDAQ:BSGM) announced that the company entered into a purchase agreement with San Antonio Methodist Hospital allowing the latter to acquire its PURE EP System, a cardiac signal processing system. According to a regulatory filing on Thursday, the company executed the deal on Sep. 30 In July, BSGM announced a leasing deal under which the Overland Park Regional Medical Center agreed to acquire the PURE EP System, marking the first transaction since its nationwide launch. "Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," BSGM Chief Commercial Officer Gray Fleming said at the time. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology," he added.Seeking Alpha • Sep 08
BioSig: No Changes To Hold Thesis Following Q2 Earnings
Summary BioSig continues to be presented with systematic challenges that place it behind other selective opportunities in med-tech. Cash flows are priced out well into the future and the predictability of these is low in the current landscape. We note updates around PURE EP continue to receive a muted market reaction upon release. Here we reiterate the hold rating on BSGM. From the Portfolio Manager's Desk Unprofitable med-tech continues to face systematic headwinds as the market looks to match mispricings in fundamentals to future expectations. However, risk-assets have caught a bid since June and that's meant high-beta names have clawed back some of the losses incurred in FY22. We've made no changes to our thesis on BioSig Technologies, Inc. (BSGM) from my previous analysis in June. We also covered BioSig in late 2020. We encourage investors to factor a data driven approach in this name until there is some fundamental value to be derived. Investment Summary We reiterate a hold rating on BSGM following Q2 earnings as systematic headwinds remain for this name. We note the stock has caught a bid since the June bounce however we argue this is likely beta related rather than some unidentified or uncorrelated premia BSGM is presenting relative to peers. With cash flows still priced well out into the future, BSGM is one to be watched from the sidelines from now for a defensively positioned equity portfolio. Rate hold on a $1 valuation. Risks to investment thesis Investing in small-cap equities comes with inherent risks that must be factored in before investment decision. Moreover, investing in commercial stage medical device companies carries its own set of downside risks. Being a neutral stance, there is both upside and downside risks to our investment thesis. In addition, small-cap equities can become disconnected from fundamentals upon news releases or wider market actions and display wide volatility in price swings. These risks pose a threat to this investment thesis and must be considered heavily into one's investment reasoning when reading this analysis. Recent upside likely beta related Quantitative analysis of recent stock returns points to the fact the upside is likely due to equity market and sector-beta rather than company-specific risk premia. As seen in Exhibit 1, since the leg upward from the July bounce, BSGM's equity beta to the S&P/500 also shifted well above 1 and has remained buoyant since. This tells us that investors are buyers of BGSM in seeking strategic equity/health care exposure, versus tactical positioning from active managers/investors. Exhibit 1. Up-shift in covariance structure accompanying the latest leg in the BGSM share price suggesting recent upside is likely equity beta versus idiosyncratic risk/return Data: Updata Further evidence of the above is seen in Exhibit 2. As noted, health care as an investment universe has caught a bid since the June bounce along with positioning in risk-assets. However, we note that BSGM's correlation to the medical devices and health care index equipment has also shifted up since May. As a result, we question if the recent upside is a function of certain investors having identified in BGSM that the market consensus has overlooked, or, just a function of sector-beta, as mentioned. We are leaning towards the latter. Exhibit 2. Correlations to med-tech and health care benchmarks also lifting since early May raising questions on where we can attribute the source of recent equity returns from in BGSM Both charts [above and below] demonstrate a tight dispersion between equity market and sector beta and the BGSM share price since it began to tick up in August Data: Updata Pure EP updates still priced in As has been the case with BSGM, the growth engine centres around PURE EP and updates around the same. However, as has also been the case this year, investors have priced in additional updates quickly and with little amplitude. Most recently on 24 August it reported that it had installed a second evaluation system at the Cleveland Clinic, expanding physician access to the company's 'signal' technology. However, the market's reaction was mute, as has been the case previously. In particular, we note the market's muted reaction to the news BSGM will reduce product evaluations down to 60 days from 180-360 days. However, there's still no revenue booked for the segment, in preparation for the commercial rollout. We mentioned in June that, "BSGM likely has revenue tailwinds set to be realised in H2 FY22, with a ramp up in sales predicted into the coming years pending a successful launch." This likely has been overshot and we now look to Q4 to see some form of how the company intends to proceed with its sales strategy looking ahead. The question then turns to what exactly are we paying for today in BSGM. Shares are priced at more than 7.1x book value, on shareholder equity of $6.8mm and book value per share of $0.15. It's also priced at 6.6x enterprise value ("EV") to book value. At this multiple we'd be paying an implied price of $1.00, suggesting the market consensus has the stock fairly discounted at its current market capitalization. Moreover, and looking at the balance sheet, we're buying into a capital structure that is weighted towards equity holders, with $596mm in tangible assets and $317mm in patents that it amortizes on a straight-line basis over 20 years. However, we're not buying into any substantiated return on any of this capital investment, and we are set to pay what looks like fair value for cash flows priced well out into the future. This degree of uncertainty keeps us trigger shy on the name. Technical factors With a lack of fundamental data, we checked the market's psychology around the stock and noted there remains a downside bias in price action. As seen in Exhibit 3, there are downside targets clustered towards the $0.85-$0.92 region. The stock has set a series of lower highs and is again testing the inner resistance line shown below. From this chart, price action appears to be bearish, and unsupportive of near-term upside.株主還元
| STEX | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -19.9% | -1.2% | -2.1% |
| 1Y | -83.9% | -12.8% | 18.8% |
業界別リターン: STEX過去 1 年間で-12.8 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: STEXは、過去 1 年間で18.8 % のリターンを上げたUS市場を下回りました。
価格変動
| STEX volatility | |
|---|---|
| STEX Average Weekly Movement | 17.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: STEXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: STEXの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2009 | 6 | Karl McPhie | www.streamex.com |
医療機器テクノロジー企業であるStreamex Corp.は、米国で電気生理学用の高度なデジタル信号処理ソリューションを提供している。同社はPURE EPプラットフォームを提供しており、心臓血管の不整脈治療のためのアブレーション処置中に電気生理学者に心臓信号データを配信している。また、トークン化された金市場向けに現実世界の資産のトークン化と交換を容易にするブロックチェーンベースのプラットフォームであるStreamex Exchangeプラットフォームを開発・運営している。さらに、ソフトウェアのサポート、メンテナンス、アップグレードサービスも提供している。同社は以前はBioSig Technologies, Inc.として知られていたが、2025年9月にStreamex Corp.に社名を変更した。Streamex Corp.は2009年に法人化され、フロリダ州ウィンターパークに本社を置いている。
Streamex Corp. 基礎のまとめ
| STEX 基礎統計学 | |
|---|---|
| 時価総額 | US$150.43m |
| 収益（TTM） | -US$500.84m |
| 売上高(TTM) | US$146.00k |
595.1x
P/Sレシオ-0.2x
PER（株価収益率STEX は割高か？
公正価値と評価分析を参照収益と収入
| STEX 損益計算書（TTM） | |
|---|---|
| 収益 | US$146.00k |
| 売上原価 | US$0 |
| 売上総利益 | US$146.00k |
| その他の費用 | US$500.99m |
| 収益 | -US$500.84m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -4.80 |
| グロス・マージン | 100.00% |
| 純利益率 | -343,044.52% |
| 有利子負債／自己資本比率 | 0% |
STEX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/21 21:43 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Streamex Corp. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2
| アナリスト | 機関 |
|---|---|
| John Todaro | Needham & Company |
| Scott Henry | Roth Capital Partners |